checkAd

    EQS-Adhoc  124  0 Kommentare Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin - Seite 4


    End of ad hoc announcement
    Language: English
    Company: Polyphor AG
    Hegenheimermattweg 125
    4123 Allschwil
    Switzerland
    Phone: +41 61 567 1600
    Fax: +41 61 567 1601
    E-mail: info@polyphor.com
    Internet: www.polyphor.com
    ISIN: CH0106213793
    Valor: POLN
    Listed: SIX Swiss Exchange
    EQS News ID: 1149986

     
    End of Announcement EQS Group News Service

    1149986  24-Nov-2020 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1149986&application_name=news&site_id=wallstreet

    Lesen Sie auch

    Seite 4 von 4




    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-Adhoc Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin - Seite 4 EQS Group-Ad-hoc: Polyphor AG / Key word(s): Agreement Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin 24-Nov-2020 / 07:30 CET/CEST Release of an ad …